Skip to main content

Clinical Trials › NCT04586023

Active, Not RecruitingPhase 3

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsored by Hoffmann-La Roche

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
751
Target enrollment
13
U.S. states
Mar 2021
Start date
Jul 2027
Expected completion

Interventions / Treatments

FenebrutinibTeriflunomidePlacebo

Conditions studied

Relapsing Multiple Sclerosis

Where this trial is running (13 sites)

Alabama1 site
Cullman
Arizona1 site
Phoenix
Torrance
Stamford
Washington D.C.
Florida1 site
Tampa
Indiana1 site
Avon
Kansas1 site
Kansas City
Foxborough
Ohio1 site
Cincinnati
Tennessee1 site
Knoxville
Virginia1 site
Falls Church
Wisconsin1 site
Milwaukee

MS centers in Alabama

Compare treatment centers near a trial site by center type, providers and trials.

View Alabama centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play